<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00139776</url>
  </required_header>
  <id_info>
    <org_study_id>A3191173</org_study_id>
    <nct_id>NCT00139776</nct_id>
  </id_info>
  <brief_title>Study Of &quot;Continuous Use&quot; Of Celecoxib Vs. &quot;Usual or Intermittent Use&quot;</brief_title>
  <official_title>Double-Blind Parallel-Group Randomized Study Of Efficacy And Safety Of &quot;Continuous Use&quot; Of Celecoxib Vs. The &quot;Usual Use&quot; Of Celecoxib In The Treatment Of Subjects With Chronic Osteoarthritis Of The Hip Or Knee Who Require an Anti-Inflammatory Medication for Control Of Their Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether &quot;continuous use&quot; of celecoxib over a 6-month period is more efficacious
      than &quot;usual or intermittent use&quot; in preventing spontaneous osteoarthritis flares of the knee
      and hip.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Flare Events Per Time of Exposure to Study Medication</measure>
    <time_frame>Period III (22 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Occurrence of First Osteoarthritis (OA) Flare</measure>
    <time_frame>Period III (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Days Free From Osteoarthritis (OA) Flare</measure>
    <time_frame>Period III (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Days in Osteoarthritis (OA) Flare</measure>
    <time_frame>Period III (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arthritis Pain Numerical Rating Scale (NRS)</measure>
    <time_frame>Period III</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment of Arthritis</measure>
    <time_frame>Period III</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment of Arthritis at Final Visit</measure>
    <time_frame>Period III (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Rescue Medication Taken (Mean)</measure>
    <time_frame>Period III (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Days on Rescue Medication</measure>
    <time_frame>Period III (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on Flare Medication</measure>
    <time_frame>Period III (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores</measure>
    <time_frame>Period III (22 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUCs) of Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores</measure>
    <time_frame>Period III (22 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">875</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Osteoarthritis, Hip</condition>
  <arm_group>
    <arm_group_label>Celecoxib - Continuous use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib - Intermittent use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.
Placebo used as flare medication when directed.</description>
    <arm_group_label>Celecoxib - Continuous use</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.
Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
    <arm_group_label>Celecoxib - Intermittent use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has been diagnosed, according to American College of Rheumatology guidelines,
             with osteoarthritis of the hip or knee and requires non-steroidal anti-inflammatory
             drugs (NSAIDs) to control their osteoarthritis pain and have access to a touch-tone
             telephone.

        Exclusion Criteria:

          -  Subject has had surgery on index joint.

          -  Subject has history of rheumatoid arthritis or fibromyalgia syndrome.

          -  Subject has active gastrointestinal or cardiovascular disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wheatridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Milford</city>
        <state>Connecticut</state>
        <zip>06776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614-7118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52001-7313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clinton</city>
        <state>Maryland</state>
        <zip>20735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manlius</city>
        <state>New York</state>
        <zip>13104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103-4019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635-0909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadephia</city>
        <state>Pennsylvania</state>
        <zip>19152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Tazewell</city>
        <state>Tennessee</state>
        <zip>37825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902-4876</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ham</city>
        <zip>3945</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13073-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04027-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2S 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5K 1K3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 3R5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1E 2C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1E 2E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <zip>N0N 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3M 3E5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <zip>C1A 5Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montague</city>
        <state>Prince Edward Island</state>
        <zip>C0A 1R0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4N 2W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 9A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 0H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Viña Del Mar</city>
        <state>V Region</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rancagua</city>
        <state>VI Región</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barranquila</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Joue Les Tours</city>
        <zip>37300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>L'Union</city>
        <zip>31240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Randalstown</city>
        <state>Co Antrim</state>
        <zip>BT41 3AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newtownabbey</city>
        <state>Co.Antrim</state>
        <zip>BT37 9QN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leslie</city>
        <state>Fife</state>
        <zip>KY6 3LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Watford</city>
        <state>Herts</state>
        <zip>WD25 0EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Canterbury</city>
        <state>Kent</state>
        <zip>CT1 3HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wigan</city>
        <state>Lancs</state>
        <zip>WN6 9EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bradwell Common</city>
        <state>Milton Keynes</state>
        <zip>MK13 8RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greenisland, Carrickfergus</city>
        <state>Northern Ireland</state>
        <zip>BT38 8TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barry</city>
        <state>Vale of Glamorgan</state>
        <zip>CF62 7EB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pound Hill, Crawley</city>
        <state>West Sussex</state>
        <zip>RH10 7DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bradford on Avon</city>
        <state>Wiltshire</state>
        <zip>BA15 1DQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Midsomer Norton</city>
        <state>Wiltshire</state>
        <zip>BA3 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bangor</city>
        <zip>BT19 1PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bath</city>
        <zip>BA2 4BY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT14 6AR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Blackpool</city>
        <zip>FY4 3AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF24 2HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cookstown</city>
        <zip>BT80 8BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trowbridge</city>
        <zip>BA14 9AR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3191173&amp;StudyName=Study%20Of%20%22Continuous%20Use%22%20Of%20Celecoxib%20Vs.%20%22Usual%20or%20Intermittent%20Use%22%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2005</study_first_posted>
  <results_first_submitted>February 20, 2009</results_first_submitted>
  <results_first_submitted_qc>March 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2009</results_first_posted>
  <last_update_submitted>June 24, 2009</last_update_submitted>
  <last_update_submitted_qc>June 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer</organization>
  </responsible_party>
  <keyword>Chronic treatment osteoarthritis, Celecoxib, Continuous Use, Intermittent Use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>111 centers in the Americas and Europe enrolled and treated subjects (2 centers in Belgium, 4 centers in Brazil, 20 centers in Canada, 5 centers in Chile, 5 centers in Columbia, 1 center in France, 15 centers in the United Kingdom, and 59 centers in the United States).</recruitment_details>
      <pre_assignment_details>17 participants completed Open-label run-in Period II and were randomized to Period III Double Blind but not treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Wash-Out: Discontinue Non-Steroidal Anti-Inflammatories</title>
          <description>Period I (14+/-2 days) wash out and discontinuation of non-steroidal anti-inflammatories (NSAIDs) leading to osteoarthritis (OA) flare.</description>
        </group>
        <group group_id="P2">
          <title>Open-Label Celecoxib Run-in Period</title>
          <description>Period II (14+/-2 days) run-in treatment with open label celecoxib to observe successful treatment of flare. Participants successfully treated randomized to 2 treatment groups in Period III (overall study).</description>
        </group>
        <group group_id="P3">
          <title>Celecoxib 200mg Continuous Use</title>
          <description>Period III Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
        </group>
        <group group_id="P4">
          <title>Celecoxib 200mg Intermittent Use</title>
          <description>Period III Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1772"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1197"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="575"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not enter Period II</title>
              <participants_list>
                <participants group_id="P1" count="575"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1197"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="875"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="322"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Randomized into Period III</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="322"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period III</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="431">Randomized 440: 9 participants not treated</participants>
                <participants group_id="P4" count="427">Randomized 435: 8 participants not treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="355"/>
                <participants group_id="P4" count="321"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="76"/>
                <participants group_id="P4" count="106"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Celecoxib 200mg Continuous Use</title>
          <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
        </group>
        <group group_id="B2">
          <title>Celecoxib 200mg Intermittent Use</title>
          <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="431"/>
            <count group_id="B2" value="427"/>
            <count group_id="B3" value="858"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="10.00"/>
                    <measurement group_id="B2" value="58.7" spread="9.6"/>
                    <measurement group_id="B3" value="58.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="317"/>
                    <measurement group_id="B2" value="303"/>
                    <measurement group_id="B3" value="620.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="238.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Flare Events Per Time of Exposure to Study Medication</title>
        <description>Number of flare events per month during Period III (calculated as number of flares divided by number of months participant was enrolled during Period III). Flare was determined using pre-defined criteria, using an interactive voice response system.</description>
        <time_frame>Period III (22 weeks)</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Flare Events Per Time of Exposure to Study Medication</title>
          <description>Number of flare events per month during Period III (calculated as number of flares divided by number of months participant was enrolled during Period III). Flare was determined using pre-defined criteria, using an interactive voice response system.</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication</population>
          <units>flare events per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.74"/>
                    <measurement group_id="O2" value="0.93" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis for primary outcome is that there is no difference in the number of flares observed between the 2 treatment arms of celecoxib 200mg continuous use and celecoxib 200mg intermittent use.
Sample size calculation: Sufficient number of participants were randomized to provide at least 80% power to detect an estimated effect size of 0.2 using a 2-sided t-test at a 0.05 significant level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment as fixed effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurrence of First Osteoarthritis (OA) Flare</title>
        <description>Time from first dose of double blind medication (start of Period III) to occurrence of first OA flare. Flare was determined using pre-defined criteria, using an interactive voice response system</description>
        <time_frame>Period III (22 weeks)</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of First Osteoarthritis (OA) Flare</title>
          <description>Time from first dose of double blind medication (start of Period III) to occurrence of first OA flare. Flare was determined using pre-defined criteria, using an interactive voice response system</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="14.0" upper_limit="22.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="8.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Days Free From Osteoarthritis (OA) Flare</title>
        <description>Number of days subject was free from OA flare divided by number of days on study medication in Period III. Flare was determined using pre-defined criteria, using an interactive voice response system.</description>
        <time_frame>Period III (22 weeks)</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Days Free From Osteoarthritis (OA) Flare</title>
          <description>Number of days subject was free from OA flare divided by number of days on study medication in Period III. Flare was determined using pre-defined criteria, using an interactive voice response system.</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication</population>
          <units>proportion of days free from OA flare</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.28"/>
                    <measurement group_id="O2" value="0.67" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment as fixed effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Days in Osteoarthritis (OA) Flare</title>
        <description>Number of days subject was in OA flare divided by number of days on study medication in Period III. Subjects may have more than one flare. Flare was determined using pre-defined criteria, using an interactive voice response system.</description>
        <time_frame>Period III (22 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Days in Osteoarthritis (OA) Flare</title>
          <description>Number of days subject was in OA flare divided by number of days on study medication in Period III. Subjects may have more than one flare. Flare was determined using pre-defined criteria, using an interactive voice response system.</description>
          <units>proportion of days in OA flare</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.28"/>
                    <measurement group_id="O2" value="0.33" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment as fixed effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arthritis Pain Numerical Rating Scale (NRS)</title>
        <description>Participant rated intensity of osteoarthritis pain on categorical scale from 0 (no pain) to 10 (worst pain). Scores analyzed as area under the curve (AUC) of participant's scores from each assessment in Period III.</description>
        <time_frame>Period III</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.
These data are presented by the weeks from the start of Period II, 2 weeks before randomization. The weeks post-randomization, Period III, are different from the study weeks i.e. includes 2 weeks from Period II.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Arthritis Pain Numerical Rating Scale (NRS)</title>
          <description>Participant rated intensity of osteoarthritis pain on categorical scale from 0 (no pain) to 10 (worst pain). Scores analyzed as area under the curve (AUC) of participant's scores from each assessment in Period III.</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.
These data are presented by the weeks from the start of Period II, 2 weeks before randomization. The weeks post-randomization, Period III, are different from the study weeks i.e. includes 2 weeks from Period II.</population>
          <units>scores on a scale * weeks</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=415 cont; n=414 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" spread="1.1"/>
                    <measurement group_id="O2" value="90.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=401 cont; n=395 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.8" spread="2.6"/>
                    <measurement group_id="O2" value="167.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=383 cont; n=363 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212.6" spread="4.1"/>
                    <measurement group_id="O2" value="234.3" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=373 cont; n=339 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272.7" spread="5.9"/>
                    <measurement group_id="O2" value="297.6" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=362; n=323 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335.9" spread="7.8"/>
                    <measurement group_id="O2" value="361.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=350 cont; n=403 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378.1" spread="9.1"/>
                    <measurement group_id="O2" value="403.9" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 16</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 20</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Assessment of Arthritis</title>
        <description>Participant's response to question &quot;Considering all the ways the osteoarthritis in your hip or knee affects you, how are you doing today?&quot; on scale from 1 (very good) to 5 (very poor). Scores analyzed as area under the curve (AUC) of participant's scores from each assessment in Period III.</description>
        <time_frame>Period III</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.
These data are presented by the weeks from the start of Period II, 2 weeks before randomization. The weeks post-randomization, Period III, are different from the study weeks i.e. includes 2 weeks from Period II.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Assessment of Arthritis</title>
          <description>Participant's response to question &quot;Considering all the ways the osteoarthritis in your hip or knee affects you, how are you doing today?&quot; on scale from 1 (very good) to 5 (very poor). Scores analyzed as area under the curve (AUC) of participant's scores from each assessment in Period III.</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.
These data are presented by the weeks from the start of Period II, 2 weeks before randomization. The weeks post-randomization, Period III, are different from the study weeks i.e. includes 2 weeks from Period II.</population>
          <units>scores on a scale * weeks</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=415 cont; n=414 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="0.68"/>
                    <measurement group_id="O2" value="71.7" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=401 cont; n=395 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.0" spread="1.55"/>
                    <measurement group_id="O2" value="133.2" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=383 cont; n=363 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.8" spread="2.48"/>
                    <measurement group_id="O2" value="188.7" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=373 cont; n=339 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236.3" spread="3.59"/>
                    <measurement group_id="O2" value="241.2" spread="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=362 cont; n=323 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292.4" spread="4.83"/>
                    <measurement group_id="O2" value="293.8" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=350 cont; n=309 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329.2" spread="5.75"/>
                    <measurement group_id="O2" value="328.9" spread="5.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 16</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.338</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 20</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.832</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.972</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Assessment of Arthritis at Final Visit</title>
        <description>Physician assessed each participant's disease symptoms on a categorical scale from 1 (very good) to 5 (very poor).</description>
        <time_frame>Period III (22 weeks)</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Assessment of Arthritis at Final Visit</title>
          <description>Physician assessed each participant's disease symptoms on a categorical scale from 1 (very good) to 5 (very poor).</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1 (very good)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (good)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242"/>
                    <measurement group_id="O2" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 (fair)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (poor)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 (very poor)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0046</p_value>
            <p_value_desc>Overall p-value Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Test of row mean score differences based on modified ridits (standardizing the mid-rank)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Rescue Medication Taken (Mean)</title>
        <description>Total amount of rescue medication (acetaminophen in milligrams [mg]) taken per month per participant</description>
        <time_frame>Period III (22 weeks)</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.
Subjects who did not take rescue medication were assumed to have taken 0mg and were included in the analysis.
Number of subjects taking rescue medication: continuous use n=220; intermittent use n=239.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Rescue Medication Taken (Mean)</title>
          <description>Total amount of rescue medication (acetaminophen in milligrams [mg]) taken per month per participant</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.
Subjects who did not take rescue medication were assumed to have taken 0mg and were included in the analysis.
Number of subjects taking rescue medication: continuous use n=220; intermittent use n=239.</population>
          <units>mg taken per month per participant</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1566" spread="4840"/>
                    <measurement group_id="O2" value="2428" spread="4974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0102</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment as fixed effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Days on Rescue Medication</title>
        <description>Days on rescue medication divided by number of days on study medication in Period III</description>
        <time_frame>Period III (22 weeks)</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication. Number of subjects taking rescue medication: continuous use n=220; intermittent use n=239.
Subjects who did not take rescue medication were calculated as 0 and included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Days on Rescue Medication</title>
          <description>Days on rescue medication divided by number of days on study medication in Period III</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication. Number of subjects taking rescue medication: continuous use n=220; intermittent use n=239.
Subjects who did not take rescue medication were calculated as 0 and included in the analysis.</population>
          <units>proportion of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.044" spread="0.102"/>
                    <measurement group_id="O2" value="0.069" spread="0.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment as fixed effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days on Flare Medication</title>
        <description>Number of days on flare medication per month per subject calculated as number of days on flare medication divided by the number of days on study medication in Period III</description>
        <time_frame>Period III (22 weeks)</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.
Subjects who did not take flare medication were calculated as 0 and included in the analysis.
Number of subjects taking flare medication: continuous use n=282; intermittent use n=339.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Days on Flare Medication</title>
          <description>Number of days on flare medication per month per subject calculated as number of days on flare medication divided by the number of days on study medication in Period III</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.
Subjects who did not take flare medication were calculated as 0 and included in the analysis.
Number of subjects taking flare medication: continuous use n=282; intermittent use n=339.</population>
          <units>days on medication per month per subject</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.589" spread="8.589"/>
                    <measurement group_id="O2" value="9.793" spread="9.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment as fixed effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores</title>
        <description>Score at end of Period III minus score at start of Period III. WOMAC assesses subject responses to 24 components regarding subscales of pain, stiffness and physical function (score range: 0=none to 4= extreme). Total score is sum of the 3 subscale scores. Negative change indicates improvement.</description>
        <time_frame>Period III (22 weeks)</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication. Number of subjects evaluable: continuous use Period III start n=428, end n=427; intermittent use Period III start n=424, end n=424</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores</title>
          <description>Score at end of Period III minus score at start of Period III. WOMAC assesses subject responses to 24 components regarding subscales of pain, stiffness and physical function (score range: 0=none to 4= extreme). Total score is sum of the 3 subscale scores. Negative change indicates improvement.</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication. Number of subjects evaluable: continuous use Period III start n=428, end n=427; intermittent use Period III start n=424, end n=424</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total WOMAC score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.71"/>
                    <measurement group_id="O2" value="4.99" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC pain subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.15"/>
                    <measurement group_id="O2" value="1.18" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC stiffness subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.07"/>
                    <measurement group_id="O2" value="0.40" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC physical function subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.51"/>
                    <measurement group_id="O2" value="3.43" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total WOMAC score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Total WOMAC score - Continuous use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
            <estimate_desc>Change in LSmean (score at end of Period III minus score at start of Period III)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total WOMAC score - Intermittent use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.60</ci_lower_limit>
            <ci_upper_limit>6.38</ci_upper_limit>
            <estimate_desc>Change in LSmean (score at end of Period III minus score at start of Period III)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC pain subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>WOMAC pain subscale - Continuous use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
            <estimate_desc>Change in LSmean (score at end of Period III minus score at start of Period III)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC pain subscale - Intermittent use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
            <estimate_desc>Change in LSmean (score at end of Period III minus score at start of Period III)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC stiffness subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>WOMAC stiffness subscale - Continuous use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <estimate_desc>Change in LSmean (score at end of Period III minus score at start of Period III)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC stiffness subscale - Intermittent use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
            <estimate_desc>Change in LSmean (score at end of Period III minus score at start of Period III)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC physical function subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>WOMAC physical function subscale - Continuous use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
            <estimate_desc>Change in LSmean (score at end of Period III minus score at start of Period III)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC physical function subscale - Intermittent use</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.42</ci_lower_limit>
            <ci_upper_limit>4.43</ci_upper_limit>
            <estimate_desc>Change in LSmean (score at end of Period III minus score at start of Period III)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Medical Outcomes Study Sleep Scale - All Assessments</title>
        <description>Subject assessment on 7 sleep associated categories. Raw scores are transformed to a 0-100 scale. Higher score indicates more of the outcome (e.g. more snoring, more adequate sleep). Score at end of Period III minus score at start of Period III.</description>
        <time_frame>Period III</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication. Subjects assessed per scale n=continuous use (cont); n=intermittent use (inter)</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Medical Outcomes Study Sleep Scale - All Assessments</title>
          <description>Subject assessment on 7 sleep associated categories. Raw scores are transformed to a 0-100 scale. Higher score indicates more of the outcome (e.g. more snoring, more adequate sleep). Score at end of Period III minus score at start of Period III.</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication. Subjects assessed per scale n=continuous use (cont); n=intermittent use (inter)</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sleep disturbance (n=415 cont; n=410 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="15.95"/>
                    <measurement group_id="O2" value="-1.4" spread="15.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Snoring (n=415 cont; n=412 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="22.36"/>
                    <measurement group_id="O2" value="0.7" spread="21.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Awaken short of breath (n=417 cont; n=411 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="16.14"/>
                    <measurement group_id="O2" value="1.1" spread="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quantity of sleep (n=417 cont; n=413 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.91"/>
                    <measurement group_id="O2" value="-0.1" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep adequacy (n=416 cont; n=413 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="24.47"/>
                    <measurement group_id="O2" value="-1.3" spread="22.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence (n=416 cont; n=413 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="14.55"/>
                    <measurement group_id="O2" value="0.6" spread="13.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep problems index I (n=416 cont; n=410 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="13.20"/>
                    <measurement group_id="O2" value="0.5" spread="13.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep problems index II (n=413 cont; n=408 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="12.29"/>
                    <measurement group_id="O2" value="-0.1" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sleep disturbance</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2712</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Snoring</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8737</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Awaken short of breath</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7703</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Quantity of sleep</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3769</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sleep adequacy</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4075</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Somnolence</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5854</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sleep problems index I</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8358</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sleep problems index II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5878</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUCs) of Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores</title>
        <description>WOMAC assesses subject responses to 24 components regarding subscales of pain, stiffness and physical function (score range: 0=none to 4= extreme). Total score is sum of the 3 subscale scores. Scores analyzed as area under the curve (AUC) of participant's WOMAC scores from each assessment in Period III.</description>
        <time_frame>Period III (22 weeks)</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.
Number of subjects evaluable: continuous use Period III start n=428, end n=427; intermittent use Period III start n=424, end n=424</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUCs) of Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Scores</title>
          <description>WOMAC assesses subject responses to 24 components regarding subscales of pain, stiffness and physical function (score range: 0=none to 4= extreme). Total score is sum of the 3 subscale scores. Scores analyzed as area under the curve (AUC) of participant's WOMAC scores from each assessment in Period III.</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.
Number of subjects evaluable: continuous use Period III start n=428, end n=427; intermittent use Period III start n=424, end n=424</population>
          <units>scores on a scale * weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total WOMAC score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="604.9" spread="313.10"/>
                    <measurement group_id="O2" value="693.6" spread="317.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC pain subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.2" spread="63.36"/>
                    <measurement group_id="O2" value="138.4" spread="65.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC stiffness subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" spread="27.57"/>
                    <measurement group_id="O2" value="62.1" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WOMAC physical function subscale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431.4" spread="229.38"/>
                    <measurement group_id="O2" value="493.6" spread="230.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC total score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC pain subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC stiffness subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC physical function subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Medical Outcomes Study Sleep Scale - Number of Participants With Optimal, Mixed and Not Optimal Sleep</title>
        <description>Transformed score scale: 1=optimal; 0=not optimal; mixed = both optimal and non-optimal sleep during Period III</description>
        <time_frame>Period III</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Outcomes Study Sleep Scale - Number of Participants With Optimal, Mixed and Not Optimal Sleep</title>
          <description>Transformed score scale: 1=optimal; 0=not optimal; mixed = both optimal and non-optimal sleep during Period III</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optimal (all scores are 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed (scores are both 1 and 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not optimal (all scores are 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis across all 3 sleep scores for Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1437</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>by general association</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in the Quality of Life Short Form-12v2 (SF-12v2) Scale Scores - All Assessments</title>
        <description>SF-12v2 is a 12 item health survey covering 7 topics. Raw scores are transformed to a 0 to 100 scale. Higher scores indicate better state of health. Score at end of Period III minus score at start of Period III.</description>
        <time_frame>Period III</time_frame>
        <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.
Subjects assessed per scale n=continuous use (cont); n=intermittent use (inter)</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Continuous Use</title>
            <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
          </group>
          <group group_id="O2">
            <title>Celecoxib 200mg Intermittent Use</title>
            <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Quality of Life Short Form-12v2 (SF-12v2) Scale Scores - All Assessments</title>
          <description>SF-12v2 is a 12 item health survey covering 7 topics. Raw scores are transformed to a 0 to 100 scale. Higher scores indicate better state of health. Score at end of Period III minus score at start of Period III.</description>
          <population>Intent to treat (ITT) population included subjects who were randomized and received at least one dose of double blind study medication.
Subjects assessed per scale n=continuous use (cont); n=intermittent use (inter)</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="431"/>
                <count group_id="O2" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical function (n=417 cont; n=413 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="23.03"/>
                    <measurement group_id="O2" value="-3.2" spread="22.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role physical (n=416 cont; n=412 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="19.93"/>
                    <measurement group_id="O2" value="-1.1" spread="20.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain (n=417 cont; n=414 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="20.11"/>
                    <measurement group_id="O2" value="-0.3" spread="21.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health (n=417 cont; n=414 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="17.60"/>
                    <measurement group_id="O2" value="-0.8" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality (n=416 cont; n=414 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="20.43"/>
                    <measurement group_id="O2" value="-3.5" spread="18.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning (n=416 cont; n=414 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="20.16"/>
                    <measurement group_id="O2" value="-3.5" spread="22.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role emotional (n=417 cont; n=413 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="18.62"/>
                    <measurement group_id="O2" value="-2.1" spread="19.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health (n=416 cont; n=413 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="15.57"/>
                    <measurement group_id="O2" value="-1.3" spread="16.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component summary(n=416 cont;n=411 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="55.55"/>
                    <measurement group_id="O2" value="-5.2" spread="57.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component summary (n=416 cont;n=411 inter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="51.59"/>
                    <measurement group_id="O2" value="-10.5" spread="55.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical function</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role physical</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Bodily pain</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>General health</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3097</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vitality</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0139</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Social functioning</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1303</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Role emotional</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1404</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental health</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4015</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical component summary</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental component summary</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0301</p_value>
            <p_value_desc>Threshold for statistical significance p&lt;0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment as fixed effect and baseline as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serious Adverse Events in Open Label run-in Period</title>
        <description>Serious adverse events occuring during the 2 week run-in period (Period II) when all participants were dosed with celecoxib 200 mg daily</description>
        <time_frame>2 weeks prior to double blind dosing</time_frame>
        <population>1197 participants entered the open-label run-in (period II) to allow observation of successful treatment of an osteoarthritis flare. 875 participants were randomized to double blind treatment (period III). 322 participants were not randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib 200mg Open Label</title>
            <description>Period II run-in (2 weeks). Celecoxib 200 mg daily until resolution of screening osteoarthritis flare as defined by IVRS</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events in Open Label run-in Period</title>
          <description>Serious adverse events occuring during the 2 week run-in period (Period II) when all participants were dosed with celecoxib 200 mg daily</description>
          <population>1197 participants entered the open-label run-in (period II) to allow observation of successful treatment of an osteoarthritis flare. 875 participants were randomized to double blind treatment (period III). 322 participants were not randomized.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitreous haemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Celecoxib 200mg Continuous Use</title>
          <description>Double blind single dose of celecoxib 200 mg daily. Placebo used as flare medication when directed.</description>
        </group>
        <group group_id="E2">
          <title>Celecoxib 200mg Intermittent Use</title>
          <description>Double blind placebo was taken once daily. Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (v11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6"/>
                <counts group_id="E2" subjects_affected="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (v11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="242"/>
                <counts group_id="E2" subjects_affected="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Eye allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Myodesopsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Breath odour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Gastrooesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Parotid gland enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tongue disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Gravitational oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Alveolar osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>American trypanosomiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Lymph gland infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Parasitic gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Repetitive strain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Snake bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hepatitis C positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hyperlipdaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tendon pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cluster headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Attention deficit / hyperactivity disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Micturition frequency decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hair texture abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Increased tendency to bruise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Ingrown hair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Myringoplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Nail operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Vasectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="431"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

